Celgene Expands Into Solid Tumor Oncology

By Life Sciences Report:Hematological cancers present special opportunities for investors. In this interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector. In the case of two companies with very different valuations, McCamant makes his preference clear.

By Peter Geschek:Few biotech firms can match Celgene's (CELG) recent success: its shares have more than doubled in the past two years. The success can largely be credited to one drug: Revlimid, one of the most successful cancer therapies ever developed.

ByWilliam Sterling:Immunotherapy, also called biologic therapy or biotherapy, utilizes the body's immune system to fight diseases such as cancer. A number of biopharmaceutical companies, large and small, are developing targeted immunotherapies to stimulate the body's immune system to work harder and smarter, with the goal to destroy certain cancers.

By William Meyers: Celgene (CELG), based in Summit, New Jersey, is a biotechnology and pharmaceutical company best known for its Revlimid therapy for multiple myeloma (MM).

By Peter Geschek:In January at the J.P. Morgan conference Celgene (CELG) CEO Bob Hugin spelled out the company's long term plan for creating more blockbuster drugs and to double sales.

ByEquity Watch: Investment Thesis Celgene Corporation (CELG) is a biopharmaceutical which engages in the discovery and commercialization of therapies for the treatment of cancer and immune-inflammatory diseases. Its primary marketed products at the moment include: Thalomid, Revlimid, Vidaza and Abraxane. The first three products are used in the treatment of blood cancer.

Celgene Corporation (CELG) January 07, 2013 11:00 am ET Executives Robert J. Hugin - Chairman, Chief Executive Officer, President and Chairman of Executive Committee Analysts Geoffrey C. Meacham - JP Morgan Chase & Co, Research Division Presentation Geoffrey C. Meacham - JP Morgan Chase & Co, Research Division

By David Zanoni:If you're looking for an established biotech company with a number of FDA approved drugs already on the market, then Celgene Corporation (CELG) is one to consider. This $28.6 billion large-cap company has five established drugs for the treatment of various cancers currently being marketed. This takes the guesswork out of investing as compared to younger biotech companies which don't yet have any FDA approved drugs on the market.